ORIC furnishes updated ORIC-944 slides via 8-K (Ex. 99.1)

ORIC Pharmaceuticals furnished an 8-K under Item 7.01 to provide updated ORIC-944 data slides for use in future investor presentations.

Rhea-AI Filing Summary

ORIC Pharmaceuticals furnished an 8-K under Item 7.01 to provide updated ORIC-944 data slides for use in future investor presentations. The materials are included as Exhibit 99.1 and incorporated by reference in the report.

The company states the information in Item 7.01 and Item 9.01 (including Exhibit 99.1) is furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except by specific reference.

8-K Event Classification

2 items: 7.01, 9.01

2 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ORIC (ORIC) announce in this 8-K?

ORIC furnished updated ORIC-944 data slides for future investor presentations, included as Exhibit 99.1.

What is Exhibit 99.1 in ORIC’s 8-K?

Exhibit 99.1 contains the company’s Updated Corporate Presentation Slides featuring ORIC-944 data.

How is the information in ORIC’s 8-K treated legally?

The Item 7.01 and Item 9.01 information, including Exhibit 99.1, is furnished, not filed, and not subject to Section 18 liabilities.

Can the materials be incorporated into other ORIC filings?

They are not incorporated by reference into other filings except where specifically referenced.

When was the event reported by ORIC?

The earliest event date reported is November 13, 2025.

What will ORIC use the updated slides for?

They are intended for use in future investor presentations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 04:25 PM EST Learn about SEC filing dates

NASDAQ false 0001796280 0001796280 2025-11-13 2025-11-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

November 13, 2025

ORIC Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39269		47-1787157
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

240 E. Grand Ave, 2nd Floor

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 388-5600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		ORIC		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 7.01 Regulation FD Disclosure.

ORIC Pharmaceuticals, Inc. (the “Company”) intends to include updated ORIC-944 data slides (the “Updated Corporate Presentation Slides”) in its corporate deck for use in future investor presentations. A copy of the Updated Corporate Presentation Slides is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

All of the information furnished in this Item 7.01 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Updated Corporate Presentation Slides
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						ORIC PHARMACEUTICALS, INC.
Date: November 13, 2025				By:		/s/ Christian V. Kuhlen
						Christian V. Kuhlen, M.D., J.D.
						General Counsel